Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
William Seeds explains what is happening in his book Peptide Protocols Volume 1: [AOD-9604] is unable to induce dimerization and thereby activation of the receptor (no competition with HGH) This fragment holds the fat-reducing and tissue repair sequence and mimics the effect of HGH on lipid metabolism, without having growth-promoting or pro-diabetic effects [AOD-9604] inhibits lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes Since AOD-9604 does not interact with growth hormone receptors, it means the peptide has the following advantages over HGH: Does not increase IGF-1 production Does not induce insulin resistance Does not stimulate muscle growth Since beta-3-adrenergic receptor activation appears to be a secondary mechanism of the AOD-9604 peptide, its primary and complete mechanism for fat mobilization and/or fat cell death within adipose tissue is not currently known
This mechanistic distinction is scientifically significant because it frames BPC-157 as a cytoprotection-associated research peptide rather than as an acid-suppressive compound
That said, side effects can occur: Common side effects (mild and transient) Injection site reactions: Redness, mild swelling, or tenderness at injection sites
A 5mg vial = 5,000mcg
Retinoids can be effective in severe adult psoriasis that does not respond to other therapies, and are sometimes combined with other treatments
IGF-1 LR3 (Long Arginine-3 IGF-1) is a synthetic, longer-acting analog of human insulin-like growth factor 1
